Several CD47 antibodies are currently being investigated in preclinical studies or Phase I & II clinical trials [42,43]; however, rather than the anti-angiogenic effect, these mimetics are sought after to overcome immune evasion of the tumor cells expressing CD47 [44,45]. This evidence concerns the gene CD47 and neoplasm.